HDAC9 and neoplasm: Although several pan-HDAC inhibitors have been approved for clinical use in tumor treatment, their therapeutic utility is limited by a poor safety profile, mainly due to their lack of selectivity, and their efficacy as monotherapies has been suboptimal [26,27].